Down Syndrome Biobank Consortium: A perspective.
Document Type
Article
Abstract
Individuals with Down syndrome (DS) have a partial or complete trisomy of chromosome 21, resulting in an increased risk for early-onset Alzheimer's disease (AD)-type dementia by early midlife. Despite ongoing clinical trials to treat late-onset AD, individuals with DS are often excluded. Furthermore, timely diagnosis or management is often not available. Of the genetic causes of AD, people with DS represent the largest cohort. Currently, there is a knowledge gap regarding the underlying neurobiological mechanisms of DS-related AD (DS-AD), partly due to limited access to well-characterized brain tissue and biomaterials for research. To address this challenge, we created an international consortium of brain banks focused on collecting and disseminating brain tissue from persons with DS throughout their lifespan, named the Down Syndrome Biobank Consortium (DSBC) consisting of 11 biobanking sites located in Europe, India, and the USA. This perspective describes the DSBC harmonized protocols and tissue dissemination goals.
Keywords
Humans, Down Syndrome, Biological Specimen Banks, Alzheimer Disease, Brain, Europe
Medical Subject Headings
Humans; Down Syndrome; Biological Specimen Banks; Alzheimer Disease; Brain; Europe
Publication Date
3-1-2024
Publication Title
Alzheimers Dement
ISSN
1552-5279
Volume
20
Issue
3
First Page
2262
Last Page
2272
PubMed ID
38270275
Digital Object Identifier (DOI)
10.1002/alz.13692
Recommended Citation
Aldecoa, Iban; Barroeta, Isabel; Carroll, Steven L; Fortea, Juan; Gilmore, Anah; Ginsberg, Stephen D; Guzman, Samuel J; Hamlett, Eric D; Head, Elizabeth; Pérez, S E; Potter, Huntington; Molina-Porcel, Laura; Raha-Chowdhury, Ruma; Wisniewski, Thomas; Yong, William H; Zaman, Shahid; Ghosh, Sujay; Mufson, Elliott J; and Granholm, Ann-Charlotte, "Down Syndrome Biobank Consortium: A perspective." (2024). Translational Neuroscience. 2396.
https://scholar.barrowneuro.org/neurobiology/2396